Screener
Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Share-based compensation | (13,653) | (9,997) | (24,249) | (17,833) |
| Other segment items: | ||||
| Amortization of intangibles | (8,097) | (8,258) | (16,194) | (16,515) |
| Depreciation of property and equipment | (118) | (264) | (237) | (777) |
| Interest income | 7,298 | 1,621 | 13,953 | 3,392 |
| Interest expense | (1,748) | (1,153) | (3,495) | (2,020) |
| Other * | 1,133 | (24,729) | (50,030) | (96,811) |
| Net income (loss) | $48,508 | $4,847 | $35,163 | $(37,604) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — net loss of $48.51M in Q2 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss increased by 900.8% year-over-year, from $4.85M to $48.51M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss has grown at a 187.8% compound annual growth rate (CAGR), from -$5.22M to $124.45M.
- What does development and licensing of biopharmaceutical assets — net loss mean?
- This metric represents the bottom-line financial performance of the development and licensing segment after accounting for all revenues, operating expenses, and non-operating items. A net loss indicates that the costs associated with drug development, licensing activities, and overhead exceed the income generated during the period. It is a critical measure of the segment's current profitability and sustainability.
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude